Prostate-specific antigen activates single-chain urokinase-type plasminogen activator

Int J Cancer. 1995 Dec 11;63(6):863-5. doi: 10.1002/ijc.2910630618.

Abstract

Prostate-specific antigen (PSA) increases in the plasma of patients with prostate cancer, and has therefore been used as a reliable tumor marker. It has been demonstrated that prostate cancer cells over-express urokinase-type plasminogen activator (uPA), which plays an important role in tumor invasion and metastasis. We found that PSA converts the single-chain proform of urokinase-type plasminogen activator (scuPA) to an active 2-chain form. The active 2-chain uPA generated from scuPA by PSA was measured by hydrolyzation of S-2444, a synthetic substrate for uPA. PSA activated scuPA time- and dose-dependently. SDS-PAGE analysis revealed that, after incubation with PSA, the intensity of the 55-kDa band of scuPA decreased concomitantly with increases in the intensity of the 2 bands at 33 kDa and 22 kDa. Amino-acid-sequence analysis indicated that PSA cleaved Lys158-Ile159, which corresponds with the site cleaved by plasmin. PSA did not enhance or impair the activity of the 2-chain form of uPA. These findings imply that PSA could be an initiator of the protease cascade involved in prostate-cancer invasion and metastasis.

MeSH terms

  • Amino Acid Sequence
  • Enzyme Activation
  • Humans
  • Male
  • Molecular Sequence Data
  • Prostate-Specific Antigen / metabolism*
  • Urokinase-Type Plasminogen Activator / metabolism*

Substances

  • Urokinase-Type Plasminogen Activator
  • Prostate-Specific Antigen